Secondary Progressive Multiple Sclerosis (SPMS)

Secondary progressive multiple sclerosis (SPMS) is a form of MS that typically follows relapsing-remitting MS (RRMS). It is characterized by steady accumulation of disability without relapses.

About 65% of patients with RRMS will develop SPMS within 15 to 20 years of diagnosis, and 90% of RRMS patients transition to SPMS within 25 years of diagnosis. The exact role of disease-modifying treatments (DMTs) in delaying this transition remains unclear.

In SPMS, there is steady buildup of disability and relapses are considered rare. When attack does occur, recovery is usually slow and, in many cases, incomplete. Existing symptoms can get worse and physical mobility becomes increasingly difficult.

Not every patient with SPMS experiences the same symptoms at the same stages of disease progression. Some people with SPMS experience relapses, and this makes it difficult to distinguish between RRMS and SPMS.

Diagnosis of SPMS

The inflammatory phase that occurs in RRMS tends to fade with time, and the number of relapses decreases gradually while disease progression and disability continues to accumulate. This phase of MS is SPMS.

The transition from RRMS to SPMS occurs slowly, so many physicians usually have a hard time distinguishing between the two phases.

Incomplete recovery from a relapse that led to permanent but stable damage is one reason symptoms can worsen over time. This incomplete recovery usually indicates RRMS or disease progression in the absence of inflammatory relapses and typically signifies transition to SPMS.

Since SPMS is difficult to diagnose, neurologists will only confirm SPMS after a minimum of 6 months of clear disease progression. Diagnosing a transition from RRMS to SPMS includes careful study of the changes in symptoms, a neurologic examination, and magnetic resonance imaging (MRI) scans.

While it’s possible, it’s often rare for patients to be diagnosed with SPMS during initial diagnosis of MS without RRMS being identified.

Management of SPMS

SPMS treatment includes the managing of symptoms and relapses. Medications, diet, exercise, and physiotherapy are the most common tools utilized during SPMS treatment.

SPMS with relapses can be managed using steroids or beta interferon­-based DMTs. Some of the FDA-approved interferon beta medications used to modify the disease course of relapsing forms of MS, including SPMS, are:

  • Avonex®
  • Extavia®
  • Betaseron®
  • Aubagio®
  • Tecfidera®
  • Gilenya®
  • Tysabri®

If these medications fail to control disease activity, the chemotherapeutic agent Novantrone® (mitoxantrone) can be used. It is the only FDA-approved drug specifically used to treat SPMS with or without relapses.

Modifiers in SPMS

With the help of neurologic examination and MRI, activity and progression of disease is evaluated at least once per year so as to track the disease course continuously and adjust treatment options accordingly.

  • If SPMS is active, a DMT will need to be started to mitigate the risk of an attack.
  • If SPMS progression does not respond to medication, it’s time to switch to a more aggressive treatment method.
  • If SPMS is inactive but still progressing with buildup of disability, rehabilitation strategies should be in place to enhance mobility and function while promoting independence.
  • If SPMS is stable without progression, treatment should focus on symptom management and improving quality of life.

SPMS and other forms of MS

SPMS is characterized by steady progression of disease as well as nerve damage with less relapses. Contrary, RRMS patients experience frequent relapses caused by inflammation. SPMS usually occurs as the second phase of disease in many patients who were first diagnosed with RRMS, while primary-progressive MS (PPMS) is the first and only phase of the disease in about 15% of individuals with MS.


Further Reading

Last Updated: Feb 27, 2019

Susha Cheriyedath

Written by

Susha Cheriyedath

Susha has a Bachelor of Science (B.Sc.) degree in Chemistry and Master of Science (M.Sc) degree in Biochemistry from the University of Calicut, India. She always had a keen interest in medical and health science. As part of her masters degree, she specialized in Biochemistry, with an emphasis on Microbiology, Physiology, Biotechnology, and Nutrition. In her spare time, she loves to cook up a storm in the kitchen with her super-messy baking experiments.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cheriyedath, Susha. (2019, February 27). Secondary Progressive Multiple Sclerosis (SPMS). News-Medical. Retrieved on December 07, 2023 from

  • MLA

    Cheriyedath, Susha. "Secondary Progressive Multiple Sclerosis (SPMS)". News-Medical. 07 December 2023. <>.

  • Chicago

    Cheriyedath, Susha. "Secondary Progressive Multiple Sclerosis (SPMS)". News-Medical. (accessed December 07, 2023).

  • Harvard

    Cheriyedath, Susha. 2019. Secondary Progressive Multiple Sclerosis (SPMS). News-Medical, viewed 07 December 2023,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Can vitamin D have positive effects on reducing cortical pathology, oxidative stress, and neurofilament light chain serum levels?